View Post

Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with standard-of-care ado-trastuzumab emtansine (T-DM1, Kadcyla®), for patients with locally advanced or metastatic HER2-positive (HER2+) breast cancer. This trial is intended to support registration in the U.S. Tucatinib is an oral, …

View Post

Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer

In Clinical Trials by Barbara Jacoby

From: PR Newswire – The initiated study will further evaluate the antitumor activity, safety and tolerability of bavituximab plus KEYTRUDA® in a gastric cancer population – Oncologie’s first global study for bavituximab plans enrollment in the US, UK, Taiwan and South Korea Oncologie, a biopharmaceutical company using an innovative precision medicine platform to develop next-generation oncology therapeutics, announced today the …

View Post

Breast Cancer Drugs More Effective Than Hormone Therapy For Some Prostate Cancers

In Clinical Trials by Barbara Jacoby

Source: The Institute of Cancer Research From: technologynetworks.com A drug used for breast and ovarian cancer is more effective than modern targeted hormone treatments at slowing progression and improving survival in some men with advanced prostate cancer, Phase III clinical trial findings reveal. The PROfound trial compared the genetically targeted cancer drug olaparib – already licensed for women with breast …

View Post

Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 Mutations

In Clinical Trials by Barbara Jacoby

By: Rachel Narozniak From: onclive.com Poziotinib, a novel drug that targets relatively uncommon EGFR and HER2 exon 20 insertion mutations, is being tested in a biomarker-driven trial of patients with non–small cell lung cancer (NSCLC) in both second-line and treatment-naïve settings. The phase II ZENITH20 trial (NCT03318939) is evaluating poziotinib monotherapy, an orally available agent, across 7 cohorts based on …

View Post

TAILORx High-Risk Group Analysis Adds to Oncotype DX Chemo-Prediction Data

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: genomeweb.com In secondary analysis of data from the TAILORx trial, researchers have added new confirming evidence that patients with high risk scores from Genomic Health’s Oncotype DX appear to benefit significantly from added chemotherapy. Investigators led by the trial’s PI Joseph Sparano shared their findings in JAMA Oncology today and also presented the analysis at the …

View Post

CytoDyn Treats First Patient in Phase 1b/2 Clinical Trial with Leronlimab (PRO 140) for Patients with Treatment-Naïve, Metastatic Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: globenewswire.com CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications announced today the injection of the first patient in a Phase 1b/2 clinical protocol with treatment-naïve metastatic triple-negative breast cancer (mTNBC). The treatment of the first patient in mTNBC with leronlimab …

View Post

New combination therapy offers bowel cancer patients extra treatment option

In Clinical Trials by Barbara Jacoby

Source: The Netherlands Cancer Institute From: PR Newswire Based on scientific findings of the Netherlands Cancer Institute a new combination treatment has been developed for patients with metastatic bowel cancer and a mutation in the BRAF gene. The results of a clinical trial in over 600 patients have revealed that patients treated with this smart combination therapy survive longer than …

View Post

Overall Survival Benefit in HR+ Advanced Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Gina Columbus From: targetedonc.com Results from the phase III MONARCH 2 trial showed that the addition of the CDK4/6 inhibitor abemaciclib (Verzenio) to fulvestrant (Faslodex) improved overall survival by 9.4 months compared with fulvestrant and placebo in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy, according to data presented at the 2019 …

View Post

FLAURA Establishes Osimertinib as 1L Therapy in EGFRm NSCLC

In Clinical Trials by Barbara Jacoby

By: Alexander M. Castellino, PhD From: medscape.com The final overall survival (OS) results from the FLAURA study have now firmly established osimertinib (Tagrisso, AstraZeneca) as front-line therapy in patients with epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC). FLAURA showed that median OS was 38.6 months for patients on osimertinib and 31.8 months for patients receiving first-generation EGFR …

View Post

Could All Patients With Advanced NSCLC Go Chemo-Free?

In Clinical Trials by Barbara Jacoby

By: Liam Davenport From: medscape.com Treatment with combination immunotherapy showed improved overall survival when compared with chemotherapy in patients with untreated advanced non-small cell lung cancer (NSCLC), even in the absence of programmed death ligand 1 (PD-L1) expression. This offers hope for chemotherapy-free treatment for all comers, say investigators. The new data come from the part 1 final analysis of …